1. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment 
Judith Maresch, Sebastian F. Schoppmann, Christiane M.R. Thallinger, Christoph C. Zielinski, Michael Hejna 
Critical Reviews in Oncology / Hematology 
Volume 82, Issue 3, Pages (June 2012)
DOI: /j.critrevonc
Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

2. Fig. 1
IHC assessment of the level of Her-2 protein and FISH analyses. (A) Tumor cells without membrane staining (IHC negativity). (B) A partial weak membrane staining in more than 10% of tumor cells with no complete circumferential staining (IHC 1+). (C) Weak to moderate circumferential membrane staining in more than 10% of tumor cells (IHC 2+) with (D), confirmed by FISH positivity. (E) Strong circumferential membrane staining in more than 10% of tumor cells (ICH 3+) (A, B, C, E, ×400 magnification). IHC 2+ confirmed by FISH, or CISH positivity and IHC 3+, are candidates for treatment with trastuzumab.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

3. Fig. 2
Suggested treatment algorithm in inoperable or metastatic gastric cancer and adenocarcinoma of the esophagus. Abbreviations: CF, cisplatin+fluoropyrimidine; DCF, docetaxel+cisplatin+fluoropyrimidine; ECF, epirubicin+cisplatin+fluoropyrimidine; EOX, epirubicin+oxaliplatin+capecitabine.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions